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ABSTRACT 
 
A rapid, selective and sensitive high 
performance liquid chromatographic method for the 
estimation of Penciclovir in human plasma has been 
developed. Chromatography was carried out on a 
Hypersil BDS C18 column using a mixture of 20mM 
Potassium dihydrogen phosphate buffer (pH 3.5 + 
0.05) and methanol (95:5 v/v) as the mobile phase.  
The eluents were monitored for the drug by UV 
detection at 254 nm. Acyclovir was used as an internal 
standard for this study. The retention times for 
Penciclovir and Acyclovir were found to be 6.2 and 
9.2 min respectively. The method was found to be 
linear in the concentration range of 50.1 ng/mL to 
7000.9 ng/mL. The method was validated as per FDA 
guidelines and was found to be suitable for 
bioequivalence and pharmacokinetic studies.  
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Fig. 1 Structure of Penciclovir  
 
 
Penciclovir (2-Amino-1, 9-dihydro-9-[4-
hydroxy-3-(hydroxymethyl) butyl]-6H-purin-6-one) is 
a guanine nucleoside analogue. It is active against 
herpes simplex virus type 1 and 2 and against 
Varicella zoster virus1-2. When famciclovir is taken 
orally it is converted to its active metabolite 
penciclovir. It inhibits enzyme thymidine kinase and 
interferes with DNA synthesis. It is official in USP 
and BP. Its empirical formula is C10H15N5O3. The 
structure of Penciclovir is shown in Fig. 1. A literature 
survey reveals the report of a few analytical methods 
for the determination of penciclovir in various 
biological fluids by HPLC3-9 and LC-MS/MS10. The 
authors now propose a simple, sensitive, accurate and 
precise RP-HPLC method for the determination of 
penciclovir by solid phase extraction technique. 
 
 
 
 
EXPERIMENTAL PROCEDURE: 
Chemicals and solvents: 
HPLC grade acetonitrile and methanol used 
in the study were obtained from Qualigens, India. 
HPLC grade water (milli Q) was prepared from 
Millipore (USA) equipment. The buffer was prepared 
by dissolving 2.72grams of Potassium dihydrogen 
phosphate in 1000 mL of milli-Q water. The pH of the 
buffer solution   was adjusted to 3.5 + 0.05 with ortho 
phosphoric acid. The working standard samples of 
Penciclovir and Acyclovir (internal standard) were 
obtained from Aurobindo Pharma (Hyderabad, India). 
Chromatographic conditions  
A Shimadzu HPLC equipment comprising 
of two LC-10AT VP pumps, VP CTO-10AS VP 
column oven, a Hypersil BDS C18 (4.6 ID X 250 mm, 
5µ particle size) column and an SPD-10A variable-
wavelength programmable UV-Visible detector was 
used for chromatographic separation. The detection of 
the compounds was monitored at 254 nm. A mobile 
phase consisting of ammonium acetate buffer (pH 3.5 
+ 0.05) and methanol in a ratio of 95:5 v/v was used 
for elution at a flow rate of 1.4 mL/min. Data was 
acquired and processed with Class VP Software. 
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Working standard solutions and the calibration curve: 
The stock solution of the analyte was 
prepared in a mixture of water and methanol (80:20 
v/v) at a free base concentration of 1 mg/mL.  The 
working standard solutions were prepared from the 
stock solution by diluting with the above solvent 
mixture. These working standard solutions were used 
to prepare the calibration curve standards and quality 
control samples. The solutions for obtaining the eight 
point standard calibration curve were prepared by 
spiking the screened blank plasma with appropriate 
amounts of penciclovir dilutions. The calibration 
curve was linear in the range of 50.1 to 7000.9 ng/mL 
(r > 0.9900). The calibration plot was drawn with a 
weighing factor of 1/X2. The quality control samples 
were prepared at four concentration levels of 50.3 
ng/mL (LLOQ QC), 150.6 ng/mL (LQC), 3301.6 
ng/mL(MQC) and 5240.7 ng/mL (HQC). The 
calibration curve results are presented in Table 1 & 2.  
The stock solution of the internal standard 
was prepared in a mixture of water and methanol 
(80:20 v/v) at a free base concentration of 1 mg/mL. 
From this, the working internal standard solution was 
prepared by suitable dilution with the above solvent 
mixture to contain 40 ng/mL.  
Sample extraction procedure: 
Five hundred micro liters of spiked plasma 
calibration curve standards and quality control 
samples were transferred to pre-labeled poly 
propylene tubes containing 50 µL of the internal 
standard. The tubes were vortexed for ten seconds. 
Five hundred micro liters of 5% ortho phosphoric acid 
solution was added to each tube and vortexed for 
another ten seconds. Each of the MCX 30mg/1CC 
cartridges was conditioned with 1mL of methanol 
followed by equilibrating with 1mL of 0.5% ortho 
phosphoric acid in water on the solid phase extraction 
chamber.  The above prepared samples were loaded on 
to the cartridges and the cartridges were washed with 
1mL of ethyl acetate followed by 1mL of 10% 
methanol in water. The cartridges were dried for about 
one minute and eluted with 1mL of 1% ammonia in 
methanol. The eluents were evaporated in a stream of 
nitrogen for 20 minutes at 50OC and the residues in the 
dried tubes were reconstituted with 0.3mL of the 
mobile phase. The contents of the tubes were vortexed 
and transferred into auto-sampler vials and then 
analyzed by injecting 50 µL of the sample into the 
column.  
 
Validation: 
 
  The proposed method has been validated11 
for selectivity, sensitivity, linearity, precision, 
accuracy, recovery, and stability and dilution integrity. 
Selectivity was determined by testing the different 
blank plasma samples (from different donors) for 
interference at the retention times of the analyte and 
the internal standard. Sensitivity was determined by 
analyzing six replicates of blank human plasma and 
the plasma spiked with the analyte at the lowest value 
in the calibration curve.  
JPRHC 
Research Article 
JPRHC             January 2010           Volume 2                Issue 1         95-102  
 
 
The intra run and inter run accuracy was 
determined by replicate analysis (n = 6) of the quality 
control samples at each level and at the limit of 
quantification value (LOQ) that was derived from the 
sample batch. Inter run precision and accuracy of the 
calibration standards were computed from the six 
calibration curves used for assay validation. The 
results are presented in Table 3.  
   Accuracy is defined as the percent relative 
(%RE) and was calculated using the formula %RE = 
(E-T) X (100/T) were E is the experimentally 
determined concentration and T is the theoretical 
concentration of the drug. Assay precision was 
calculated using the formula %RSD = (SD/M) X (100) 
were M is the mean of the experimentally determined 
concentration and SD is standard deviation of M 
Dilution integrity was performed with samples falling 
above the upper concentration limits of the calibration 
curve. For this, a concentration of double the 
uppermost calibration standard was diluted two fold 
and four fold with blank plasma. Six replicates each of 
the diluted samples were processed and analyzed for 
accuracy and precision.  
The auto – sampler or wet extracted stability 
of the processed sample was evaluated by comparing 
the extracted plasma samples that were injected 
immediately (comparison samples, t0), with the 
samples that were injected after keeping in auto-
sampler at 100C for 20.0 hrs (stability samples). The 
stability of spiked human plasma samples stored at 
room temperature (Bench top stability) was evaluated 
for a period of six hours and compared with that of the 
freshly prepared samples. The freeze-thaw stability 
was assessed by comparing the stability of the samples 
that had been frozen and thawed three times, with that 
of the freshly spiked quality control samples. The 
stability of spiked human plasma stored at -700C (long 
– term stability) was evaluated by analyzing the 
quality control samples that were stored at -700C for 
seven days together with the freshly spiked calibration 
standards and the quality control samples. All stability 
evaluations were based on back-calculated 
concentrations. The stability data is presented in Table 
4. Analytes were considered stable if the deviations of 
the mean test responses were within 15% of the 
freshly prepared or comparison samples.  
The representative chromatogram obtained from 
processing of blank plasma (Fig.3.) shows that the 
assay procedure is specific as no interfering peaks 
were observed in the blank plasma at retention times 
corresponding to the drug and the internal standard. 
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CONCLUSION
The proposed HPLC method is simple, selective, 
precise and accurate for quantification
Penciclovir in human plasma. The method may be 
useful for bio-availability and bio-equivalence studies 
onthedrug.
                
 
Fig. 2 Representative Chromatogram of Penciclovir extracted from plasma  
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Fig. 3 Representative Chromatogram of extracted blank plasma sample
 
Table 1. Summary of calibration parameters  
 
Calibration curve Slope Intercept Correlation coefficient 
1 0.000079 0.00012 0.9992 
2 0.000077 0.00471 0.9995 
3 0.000082 -0.00480 0.9992 
4 0.000079 -0.00101 0.9989 
5 0.000079 0.00553 0.9956 
6 0.000077 0.00619 0.9967 
 
Table 2.  Precision of plasma calibration curve standards (n = 6) 
Nominal concentration 
(ng/mL) 
Mean  
calculated concentration   Percent 
Coefficient variation 
Percent 
Relative Error 
50.1 50.03 4.1 0.17 
150.0 153.00 5.0 -1.97 
750.2 738.77 7.7 1.52 
1500.4 1554.20 7.3 -3.59 
3000.8 2992.36 4.9 0.28 
4001.0 4005.92 3.8 -0.12 
5250.7 5291.35 5.0 -0.77 
7000.9 6843.27 4.0 2.25 
JPRHC 
Research Article 
JPRHC             January 2010           Volume 2                Issue 1         95-102  
 
 
 
 
Table 3. Precision and accuracy 
 
 
 
 
 
                                                                                  Table 4. Stability data 
 
 
QC ID 
Nominal 
concentration 
(ng/mL) 
Intra batch  Inter batch 
n 
Mean 
concentration 
observed  
% CV % RE n 
Mean 
concentration 
observed  
% CV % RE 
LLOQ QC 50.3 6 51.61 11.8 -2.63 36 48.48 9.1 3.59 
 LQC 150.6 6 150.96 6.7 -0.27 36 148.65 4.3 1.26 
MQC 3301.6 6 3217.71 8.8 2.54 36 3321.02 8.0 -0.59 
HQC 5240.7 6 5268.49 7.2 -0.53 36 5171.98 6.8 1.31 
 
 
 
 
Details of Stability 
Experiment 
n 
Spiked concentration 
ng/mL 
Mean calculated 
comparison 
sample 
concentration 
Mean calculated  
stability sample 
concentration 
Mean 
percent 
change 
Bench top stability HQC 6 5240.7 4821.77 5002.75 -3.62 
Bench top stability LQC 6 150.6 152.05 147.43 3.13 
Auto-sampler  stability HQC 6 5240.7 5043.37 5028.97 0.29 
Auto-sampler  stability LQC 6 150.6 152.82 147.00 3.96 
Freeze-thaw stability HQC 6 5240.7 4821.77 5122.23 -5.87 
Freeze-thaw stability LQC 6 150.6 152.05 149.65 1.60 
Dry extract stability HQC 6 5240.7 5043.37 5215.13 -3.29 
Dry extract stability LQC 6 150.6 152.82 146.65 4.21 
Long term stability HQC 6 5240.7 5307.70 4881.95 8.72 
Long term stability LQC 6 150.6 155.87 145.15 7.38 
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